BACKGROUND: Frailty is associated with worse health-related quality of life (HRQOL) in older adults and worse clinical outcomes in adults of all ages with end stage renal disease (ESRD). It is unclear whether frail adults of all ages with ESRD are more likely to experience worse HRQOL. OBJECTIVE: The goal of this study was to identify factors associated with worsening HRQOL in this population. DESIGN, SETTING AND MEASUREMENTS: We studied 233 adults of all ages with ESRD enrolled (11/2009-11/2013) in a longitudinal cohort study. Frailty status was measured at enrollment and HRQOL was reported (Excellent, Very Good, Good, Fair or Poor) at the initial assessment and follow-up (median follow-up 9.4 months). We studied factors associated with Fair/Poor HRQOL at follow-up using logistic regression and factors associated with HRQOL change using multinomial regression. All models were adjusted for age, sex, race, education, BMI, diabetes status, history of a previous transplant, type of dialysis and time between assessments. RESULTS: Fair/Poor HRQOL was reported by 28% at initial assessment and 33% at follow-up. 47.2% of participants had stable HRQOL, 22.8% better HRQOL, and 30.0% worse HRQOL at follow-up (P<0.001). In adjusted models, only frailty was associated with Fair/Poor HRQOL at follow-up (OR: 2.79, 95% CI: 1.32-5.90) and worsening HRQOL at follow-up (RR: 2.91, 95%CI: 1.08-7.80). CONCLUSIONS: Frail adults of all ages with ESRD are more likely to experience fair/poor HRQOL and worsening HRQOL over time. Frailty represents a state of decreased physiologic reserve that impacts not only clinical outcomes but also the patient-centered outcome of HRQOL.
BACKGROUND: Frailty is associated with worse health-related quality of life (HRQOL) in older adults and worse clinical outcomes in adults of all ages with end stage renal disease (ESRD). It is unclear whether frail adults of all ages with ESRD are more likely to experience worse HRQOL. OBJECTIVE: The goal of this study was to identify factors associated with worsening HRQOL in this population. DESIGN, SETTING AND MEASUREMENTS: We studied 233 adults of all ages with ESRD enrolled (11/2009-11/2013) in a longitudinal cohort study. Frailty status was measured at enrollment and HRQOL was reported (Excellent, Very Good, Good, Fair or Poor) at the initial assessment and follow-up (median follow-up 9.4 months). We studied factors associated with Fair/Poor HRQOL at follow-up using logistic regression and factors associated with HRQOL change using multinomial regression. All models were adjusted for age, sex, race, education, BMI, diabetes status, history of a previous transplant, type of dialysis and time between assessments. RESULTS: Fair/Poor HRQOL was reported by 28% at initial assessment and 33% at follow-up. 47.2% of participants had stable HRQOL, 22.8% better HRQOL, and 30.0% worse HRQOL at follow-up (P<0.001). In adjusted models, only frailty was associated with Fair/Poor HRQOL at follow-up (OR: 2.79, 95% CI: 1.32-5.90) and worsening HRQOL at follow-up (RR: 2.91, 95%CI: 1.08-7.80). CONCLUSIONS: Frail adults of all ages with ESRD are more likely to experience fair/poor HRQOL and worsening HRQOL over time. Frailty represents a state of decreased physiologic reserve that impacts not only clinical outcomes but also the patient-centered outcome of HRQOL.
Entities:
Keywords:
End stage renal disease; frailty; Health-related quality of life
Authors: Karen Bandeen-Roche; Qian-Li Xue; Luigi Ferrucci; Jeremy Walston; Jack M Guralnik; Paulo Chaves; Scott L Zeger; Linda P Fried Journal: J Gerontol A Biol Sci Med Sci Date: 2006-03 Impact factor: 6.053
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Claudio Bilotta; Ann Bowling; Alessandra Casè; Paola Nicolini; Sabrina Mauri; Manuela Castelli; Carlo Vergani Journal: Health Qual Life Outcomes Date: 2010-06-08 Impact factor: 3.186
Authors: Meredith C Masel; James E Graham; Timothy A Reistetter; Kyriakos S Markides; Kenneth J Ottenbacher Journal: Health Qual Life Outcomes Date: 2009-07-23 Impact factor: 3.186
Authors: Mara A McAdams-DeMarco; Andrew Law; Megan L Salter; Brian Boyarsky; Luis Gimenez; Bernard G Jaar; Jeremy D Walston; Dorry L Segev Journal: J Am Geriatr Soc Date: 2013-05-27 Impact factor: 7.538
Authors: Jon Kobashigawa; Darshana Dadhania; Sangeeta Bhorade; Deborah Adey; Joseph Berger; Geetha Bhat; Marie Budev; Andres Duarte-Rojo; Michael Dunn; Shelley Hall; Meera N Harhay; Kirsten L Johansen; Susan Joseph; Cassie C Kennedy; Evan Kransdorf; Krista L Lentine; Raymond J Lynch; Mara McAdams-DeMarco; Shunji Nagai; Michael Olymbios; Jignesh Patel; Sean Pinney; Joanna Schaenman; Dorry L Segev; Palak Shah; Lianne G Singer; Jonathan P Singer; Christopher Sonnenday; Puneeta Tandon; Elliot Tapper; Stefan G Tullius; Michael Wilson; Martin Zamora; Jennifer C Lai Journal: Am J Transplant Date: 2018-12-22 Impact factor: 8.086
Authors: Christine E Haugen; Nadia M Chu; Hao Ying; Fatima Warsame; Courtenay M Holscher; Niraj M Desai; Miranda R Jones; Silas P Norman; Daniel C Brennan; Jacqueline Garonzik-Wang; Jeremy D Walston; Adam W Bingaman; Dorry L Segev; Mara McAdams-DeMarco Journal: Clin J Am Soc Nephrol Date: 2019-03-19 Impact factor: 8.237
Authors: Nadia M Chu; Xiaomeng Chen; Silas P Norman; Jessica Fitzpatrick; Stephen M Sozio; Bernard G Jaar; Alena Frey; Michelle M Estrella; Qian-Li Xue; Rulan S Parekh; Dorry L Segev; Mara A McAdams-DeMarco Journal: Am J Nephrol Date: 2020-07-08 Impact factor: 3.754
Authors: Alvin Thomas; Christine E Haugen; Alexandra Mountford; Fatima Warsame; Rachel Berkowitz; Sunjae Bae; Charles H Brown; Daniel C Brennan; Karin J Neufeld; Michelle C Carlson; Dorry L Segev; Mara McAdams-DeMarco Journal: J Am Soc Nephrol Date: 2018-04-23 Impact factor: 10.121
Authors: Mara A McAdams-DeMarco; Hao Ying; Alvin G Thomas; Fatima Warsame; Ashton A Shaffer; Christine E Haugen; Jacqueline M Garonzik-Wang; Niraj M Desai; Ravi Varadhan; Jeremy Walston; Silas P Norman; Dorry L Segev Journal: Transplantation Date: 2018-10 Impact factor: 4.939
Authors: Fatima Warsame; Hao Ying; Christine E Haugen; Alvin G Thomas; Deidra C Crews; Tariq Shafi; Bernard Jaar; Nadia M Chu; Dorry L Segev; Mara A McAdams-DeMarco Journal: Am J Nephrol Date: 2018-09-03 Impact factor: 3.754
Authors: Christine E Haugen; Alvin G Thomas; Nadia M Chu; Ashton A Shaffer; Silas P Norman; Adam W Bingaman; Dorry L Segev; Mara McAdams-DeMarco Journal: Am J Transplant Date: 2019-12-12 Impact factor: 8.086
Authors: Christine E Haugen; Alden Gross; Nadia M Chu; Silas P Norman; Daniel C Brennan; Qian-Li Xue; Jeremy Walston; Dorry L Segev; Mara McAdams-DeMarco Journal: J Gerontol A Biol Sci Med Sci Date: 2021-02-25 Impact factor: 6.053